Ken Griffin Citadel Advisors
Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$820M |
| 2 |
Microsoft
MSFT
|
+$811M |
| 3 |
McDonald's
MCD
|
+$804M |
| 4 |
Coca-Cola
KO
|
+$655M |
| 5 |
Amazon
AMZN
|
+$646M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SCHW
Charles Schwab
SCHW
|
+$1.64B |
| 2 |
Invesco QQQ Trust
QQQ
|
+$1.1B |
| 3 |
Strategy Inc
MSTR
|
+$564M |
| 4 |
Kroger
KR
|
+$558M |
| 5 |
Danaher
DHR
|
+$494M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 3.33% |
| 2 | Healthcare | 3.23% |
| 3 | Consumer Discretionary | 2.55% |
| 4 | Financials | 2.55% |
| 5 | Industrials | 1.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VTYX
11826
PUT
DELISTED
Ventyx Biosciences
VTYX
| $40.9K | ﹤0.01% |
19,100
-2,300
| -11% | -$3.71K |
|
11827
PUT
Citius Pharmaceuticals
CTXR
$20.7M
| $40.9K | ﹤0.01% |
25,700
+15,900
| +162% | +$14.6K |
|
11828
Retractable Technologies
RVP
$20.7M
| $40.8K | ﹤0.01% |
63,798
-89,166
| -58% | -$62K |
|
11829
Cosmos Holdings
COSM
$13.5M
| $40.6K | ﹤0.01% |
+96,731
| New | +$41K |
|
11830
CALL
CarParts.com
PRTS
$47.1M
| $40.6K | ﹤0.01% |
5,480
-9,570
| -64% | -$81.8K |
|
11831
Offerpad Solutions
OPAD
$21.5M
| $40.4K | ﹤0.01% |
+4,443
| New | +$51.1K |
|
|
APLT
11832
CALL
DELISTED
Applied Therapeutics
APLT
| $40.4K | ﹤0.01% |
129,800
-8,600
| -6% | -$3.33K |
|
11833
PUT
Entravision Communication
EVC
$832M
| $40.4K | ﹤0.01% |
17,400
+10,800
| +164% | +$21.8K |
|
|
ADVB
11834
Advanced Biomed Inc
ADVB
$14.8M
| $40.4K | ﹤0.01% |
2,883
+2,322
| +414% | +$68.4K |
|
|
BCG
11835
Binah Capital Group
BCG
$26.3M
| $40.3K | ﹤0.01% |
+19,856
| New | +$43K |
|
|
GELS
11836
Gelteq Ltd
GELS
$6.21M
| $40.1K | ﹤0.01% |
23,201
+8,036
| +53% | +$13.2K |
|
11837
CALL
Douglas Elliman
DOUG
$185M
| $40.1K | ﹤0.01% |
17,300
-500
| -3% | -$1.07K |
|
|
IOBT
11838
DELISTED
IO Biotech
IOBT
| $40.1K | ﹤0.01% |
28,866
-16,689
| -37% | -$19.1K |
|
11839
CALL
Ring Energy
REI
$357M
| $40.1K | ﹤0.01% |
50,500
+35,700
| +241% | +$30.2K |
|
11840
PUT
Neumora Therapeutics
NMRA
$301M
| $40K | ﹤0.01% |
54,500
-48,100
| -47% | -$36.4K |
|
11841
PUT
Anixa Biosciences
ANIX
$108M
| $39.9K | ﹤0.01% |
12,100
-11,300
| -48% | -$32.3K |
|
11842
CALL
Mind CTI
MNDO
$20.6M
| $39.3K | ﹤0.01% |
28,300
+17,700
| +167% | +$27.2K |
|
11843
PUT
Taysha Gene Therapies
TSHA
$1.94B
| $39.3K | ﹤0.01% |
17,000
+12,300
| +262% | +$26.7K |
|
11844
Sentage Holdings
SNTG
$5.55M
| $39.2K | ﹤0.01% |
+22,029
| New | +$38.1K |
|
11845
PUT
Arbe Robotics
ARBE
$97.8M
| $39.2K | ﹤0.01% |
22,000
-2,200
| -9% | -$3.14K |
|
|
CIF
11846
DELISTED
MFS Intermediate High Income Fund
CIF
| $39K | ﹤0.01% |
22,401
-21,756
| -49% | -$36.7K |
|
|
NFGC
11847
CALL
New Found Gold
NFGC
$649M
| $38.9K | ﹤0.01% |
27,400
+27,300
| +27,300% | +$35.2K |
|
|
NFGC
11848
PUT
New Found Gold
NFGC
$649M
| $38.9K | ﹤0.01% |
27,400
-12,700
| -32% | -$16.4K |
|
11849
PUT
Zevia
ZVIA
$102M
| $38.6K | ﹤0.01% |
12,000
+10,400
| +650% | +$27.4K |
|
|
TMQ
11850
PUT
Trilogy Metals
TMQ
$646M
| $38.6K | ﹤0.01% |
28,600
+27,700
| +3,078% | +$39K |
|
Similar funds
Ken Griffin's Q2 2025 Portfolio in Review
As of Q2 2025, Ken Griffin held 15,819 positions worth $576B, up 9.2% from $527B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Ken Griffin withdrew a net $29.1B in Q2 2025, closing 3,524 positions and reducing 5,141 holdings. Its most notable exit was Kroger, an estimated $558M position sold in full.
By sector, the portfolio is most concentrated in Technology at 3.3% of assets, up from 2.9% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Ken Griffin opened a new position in Walmart Inc worth $401M.
- Ken Griffin's largest Q2 2025 buy was Walmart Inc: 4,099,492 shares worth $401M.
- Ken Griffin added most to NVIDIA in Q2 2025, an estimated $820M increase.
- Ken Griffin's biggest Q2 2025 reduction was Charles Schwab, cutting an estimated $1.64B.
- Ken Griffin fully exited Kroger in Q2 2025, selling an estimated $558M.
- Ken Griffin's ten largest holdings make up 27% of its $576B portfolio in Q2 2025.
- Ken Griffin opened 1,459 new positions and closed 3,524 in Q2 2025.
- Ken Griffin's portfolio value rose 9.2% quarter-over-quarter to $576B.
Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.